The company's portfolio consists of a few commercialized products and multiple clinical and pre-clinical product candidates. 12. Someone is "mistaken" here. Which company is going to get bought? Biotech/FDA. This submission marks the first marketing application submission for a gene therapy product for any type of hemophilia. Given that the FDA is yet to approve a NASH drug, it is worth taking a risk with this one-trick pony. Oncology and gene therapy were the subjects of acquisitions this year. Scott has had the most success in trading/investing in smaller cap growth companies. GLOBAL MARKETS-Stocks buoyed by cheery data after BOJ damp squib, Nouriel Roubini: There's a massive disconnect between markets and the Fed, U.S. natgas price slump pushes 'widow maker' toward unusual contango, Germany must speed hydrogen plans this year - gas pipeline group OGE, Ian Bremmer: We're in a hot war with Russia. The most recent update provided by the company suggests it may take several quarters for the issue to be resolved. ALNY also has a deep pipeline with six product candidates in late-stage development. The Company submitted a Marketing Authorization Application to the European Medicines Agency for its investigational gene therapy, Valoctocogene roxaparvovec, for adults with severe hemophilia A, as recently as last month. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Markets. Let's take a look at some of the biotech companies that have been in the acquisition crosshairs for quite some time. Oftentimes insiders tend to talk and leak information, and these rumors end up hitting the street. Scott uses his ability to read situations, emotion, charts, times and sales, historical data, and macroeconomic and other market forces to predict stock price movements, in both short and longer terms situations.. Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. It was also approved in the EU. Written by earnings call is. Its lead product candidate, pimavanserin, designed to treat Parkinson's Disease Psychosis (PDP) has completed a. e have heard similar buzz over the last few months, and as mentioned, the buzz makes sense to us, in no small part because Acadia has had quite an epic stock run over the last year. Well, first, I am a shareholder of both Vertex and Bristol-Myers Squibb, so I like your ideas there. If there's anything we've missed, or any additional information you'd like to see, please reach out and let us know. 3 Top Stocks to Buy Now and Hold Forever, Warren Buffett Is Raking in $4.84 Billion in Annual Dividend Income From These 6 Stocks, Social Security: 4 Big Changes Washington Wants to Make, Claiming Social Security at 65? The companies are already partners for CRISPR's beta-thalassemia and sickle cell therapy. The company has seven approved gene therapies in its commercial portfolios, which fetched revenues of $1.86 billion in 2021. Create your Watchlist to save your favorite quotes on Nasdaq.com. Acquisition rumors have swirled around specialty biotech BioMarin Pharmaceutical (NASDAQ: BMRN) for years now.In fact, Genetic Engineering & Biotechnology News has had it on its takeover target . I also agree with you that Vertex, if there's going to be one of those massive big pharma mergers like we've seen over the last 20 years, some of those massive deals, I think Vertex would be an excellent candidate to be acquired by a bigger company. In December 2019, Intra-Cellulars first drug named CAPLYTA was approved by the FDA for the treatment of adult patients with schizophrenia. 9. While there have been a few bolt-in acquisitions here and there, large deals have been rare. Powered by Madgex Job Board Software. A Roth Capital Partners analyst remarked in May of this year that he believes ACAD is on big pharmas' radar as an acquisition target. Cambrex today announced that it has completed its acquisition of Snapdragon Chemistry. Bristol-Myers Squibb (BMY) acquiring Celgene for $74 billion in January remains the most expensive acquisition of this year. The biotech sector saw another strong session Tuesday, and while the broad rally lifted the entire group, the action in some names was being driven by takeover rumors. I think these would be great for the investors, mostly because I think maybe their valuations are a little inflated. These deals haven't come cheap, however. Additional disclosure: Disclaimer: This article is intended for informational and entertainment use only, and should not be construed as professional investment advice. BioMarin is almost every analyst's favorite takeover candidate. Copyright 2023 InvestorPlace Media, LLC. Ionis (NASDAQ:IONS) is commercial-stage biopharma developing RNA-targeted therapy using antisense technology that can control gene expression in a cell using antisense oligonucleotides (ASO). AMRN closed Friday's trading at $24.12, up 4.92%. You Might Regret That, History Suggests the S&P 500 Could Soar in 2023. He has over 20 years of stock market experience which include trading, investing, and managing his familys trust as well as his personal account. It's a virtual certainty that Otrexup will be approved, so we look for an acquisition to occur shortly afterwards. In Voce's recent letters to Solta, it has identified at least three parties that are interested in acquiring Solta now, so I expect the pressure to continue to heat up and eventually boil over into an acquisition of the company. BioMarin remains on track to submit a Biologics License Application for Valoctocogene roxaparvovec to the FDA by the end of this year. In fact, the second quarter hit a five-year low in both the value and number of biopharma transactions. Keith Speights owns Bristol Myers Squibb and Vertex Pharmaceuticals. Click to get this free report Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report Adaptimmune Therapeutics PLC (ADAP) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report To read this article on Zacks.com click here. For this story, BioPharma Dive looked only at companies developing human medicines. They could develop that in combination. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. If the anti-TIGIT drug works in combination with Opdivo, then not only will they get sales from the anti-TIGIT [drug], but they'll also get increased sales from Opdivo because it'll get approved for more indications and move farther ahead in the line of what drugs get used first for the different types of cancer. The Company submitted a Marketing Authorization Application to the. The rumor involved Pfizer (PFE) being the acquirer. Cellectis announced today that Cibus Global LLC and Calyxt, Inc. (NASDAQ: CLXT) (Calyxt), announced that Calyxt and Calypso Merger Subsidiary, LLC, a Delaware limited liability company and wholly-owned subsidiary of Calyxt, entered into an Agreement and Plan of Merger with Cibus and certain other parties named therein (the Merger Agreement), pursuant to which, subject to the terms and conditions thereof, Calyxt and Cibus will merge in an all-stock transaction. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines. On the date of publication, Shanthi Rexaline did not have (either directly or indirectly) any positions in the securities mentioned in this article. The top ten deals in the industry totaled $97 billion in 2020, led by the $39-billion buyout of Alexion Pharmaceuticals ( ALXN) - Get Free Report late in the year by AstraZeneca ( AZN) - Get Free. With $94.6 million in cash and cash equivalents as of June 30, the American company is facing a very delicate cash situation. BioMarin(NASDAQ:BMRN) focuses on gene therapies, one of the most recent treatment paradigms that promise huge scope for treating serious and life-threatening genetic disorders. No. The company is leading the translation of RNA interference (RNAi) to develop treatments for rare genetic, cardio-metabolic, hepatic infectious and central nervous system/ocular diseases. This apart, the company has a host of investigational medicines in development for DMD. Example: +water -Europe In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. Shanthi is a contributor to InvestorPlace.com as well as a staff writer with Benzinga. Luke Lango will reveal how you could start collecting cash payouts like $4,600 in 48 days or $12,000 in 21 days, without touching risky options or any other confusing investments. As part of the acquisition of Celgene, the . When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. Sold CoTherix, Inc. to Actelion Pharmaceuticals Ltd.: Mr. Rosen served on the Board of Directors of CoTherix, Inc. Actelion Pharmaceuticals bought out CoTherix for $420M. David Callan was actively involved SRI Surgical (Formerly Nasdaq listed STRC) unsolicited offer bid and eventual sale of the company. If you're going to give me a quick up-front profit, I'm definitely going to take it and I'm not going to complain about it. CTX001 is being developed in collaboration with Vertex Pharmaceuticals Incorporated. Sold Kos Pharmaceuticals to Abbott Laboratories (ABT): Mr. Adams served as the President and Chief Executive Officer of Kos Pharmaceuticals, Inc. Abbott Laboratories bought out Kos Pharmaceuticals for $78 a share, or a 56% premium over the current share price. Leading gene-editing biotechs CRISPR Therapeutics and Intellia are likely to be acquired at some point. Pharma giant Pfizer recently announced that it will acquire Arena. Freight. Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. The downside is that I'm not really sure Vertex wants to get into the CAR-T business, which is basically the other half of CRISPR's clinical pipeline. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. His work with diagnostics development give him a strong background in immunology which is leveraged in evaluating immunology focused approaches. 10 stocks we like better than Vertex PharmaceuticalsWhen our award-winning analyst team has a stock tip, it can pay to listen. Rubraca competes with other PARP inhibitors like Lynparza and Zejula. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. Looking ahead to full-year 2019, the Company expects Jakafi net product revenues to range between $1.65 billion and $1.68 billion, reflecting 20% to 22% growth over the prior year. Sold GenPharm International, Inc. to Medarex, which was then acquired by Bristol-Myers Squibb (BMY): Mr. Rosen served as Director of Corporate Development at GenPharm International. Are you interested in learning more about small- and mid-cap biotech stocks with exceptional growth potential and some of the hottest takeover targets of the industry? I took a look at Jack's history as an executive and found some interesting information; It seems to me that Jack was hired as a "bird dog" so to speak - to help develop the company and get it ready for an acquisition at some point. Get the free daily newsletter read by industry experts, The free newsletter covering the top industry headlines. Nasdaq In this year's M&A deals, most of the acquisition targets were those that were involved in developing cancer drugs or gene therapies. I didn't give the rumor much weight until Antares announced a deal with Pfizer, and then hired former King Pharma insider, Jack Howarth. Sold Pharsight Corporation to Tripos International: Mr. Rosen served on the Board of Directors of Pharsight Corporation. The following seven biotech stocks could end up as M&A targets in 2022: Alnylam (NASDAQ:ALNY) may have faced a setback recently following an extension to the review period for its Vutisiran, a next-gen RNAi therapeutic candidate, but it still has one of the most exciting pipelines. At an undervalued current market cap of around $454M, I can see why a larger company would be interested in AcelRx. Type a symbol or company name. Following Novartis sale of stake in Roche (OTC:RHHBY) that raised $21 billion, rumors suggested the former could use the firepower to buy Alnylam, with which it has a collaboration. Mergers & Acquisitions (M&As) are back in focus in the biotech sector as Merck MRK recently acquired Acceleron Pharma for $180 per share in cash for an approximate total equity value of $11.5 . . Brian, what are some acquisitions that you'd like to. 2019 saw more than 25 acquisition deals executed in the biotech sector, of which 14 were billion-dollar deals. There weren't that many biotech acquisitions in 2021, at least, not compared to other previous years. Aegis Sciences Corporation, a health care testing laboratory based in Nashville, Tenn., today announced its acquisition of the HealthTrackRx Toxicology line of business. Places you can follow Scott are: www.stockmatusow.com www.twitter.com/StockMatusow @StockMatusow http://www.facebook.com/TheScottMatusowShow Places to follow Dan are: https://twitter.com/biosleuth. In early 2017, the rumor mill was spinning with whispers of Gilead (GILD) close to acquiring Incyte. Click on an acquiring company to pull up more information, and scroll to the bottom of the page to read how this information was collected and organized. (2016). The companys cell therapy candidates include Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cells, which use genetically engineered T-cell receptors, next-generation Tumor Infiltrating Lymphocytes (TiLs) where a patients own T-cells are co-administered with next-generation technology, and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. 1. Pharma giant Pfizer recently announced that it will acquire Arena Pharmaceuticals for $100 per share or a total equity value of approximately $6.7 billion to further expand its portfolio. All rights reserved. We at Biotech Investments see several catalysts that could make Intra-Cellular Therapies an interesting acquisition target. *Premiums are calculated from the closing price of the acquired company's shares on the previous trading day. Ra Medical Systems (NYSE American: RMED) announces a realignment of its board of directors in conjunction with the recently announced merger with Catheter Precision, Inc. David Jenkins has joined the board as Executive Chairman and James Caruso has been named director. Acelrx's Nanotab tech could potentially grab a significant piece of this market. Sold Sepracor to Dainippon Sumitomo: Mr. Adams served as President and Chief Executive Officer of Sepracor Inc. Dainippon Sumitomo bought out Sepracor for $2.6B, or a 48% premium over the current share price. The acquisition will give Merck access to Accelereons promising pipeline candidate sotatercept which is being evaluated for the treatment of pulmonary arterial hypertension (PAH), a progressive and life-threatening blood vessel disorder. Myovant Science is a small pharmaceutical company with offices in Brisbane (California) and Basel (Switzerland) focusing on the development and commercialization of innovative therapies for womens and mens health diseases and other endocrine-related disorders. Cash position at the end of the fiscal year was at $1.52 billion. Here's the Stock to Buy Now, Join Nearly 1 Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. Scott is an independent investor/writer/trader and team leader of StockMatusow.com. Now, let's take a speculative twist in our discussion about acquisitions. The FDA decision on Pemigatinib is expected by May 30, 2020. We believe there is merit to the current rumors surrounding AcelRx. Tripos International bought out Pharsight for $57M. The surge in transactions in the pharmaceutical industry saw 16 deals during 2022 - seemingly the largest number in a decade, worth several billion dollars in value. Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. Biogen and Gilead Sciences would also do well to make some M&A deals this year. PwC also expects large-sized deals, valued at $50 billion or more, for diversifying into adjacent therapeutic areas. Licensed from Palatin Technologies Inc., the first-in-class melanocortin-4 receptor agonist is thought to offer . The pipeline progress has been encouraging. Keep track of M&A as it happens with this database. Enclose phrases in quotes. Ionis has clinical study collaborations and strategic partnerships with the high-and-mighty of the industry, including Roche, Biogen (NASDAQ:BIIB) and AstraZeneca (NASDAQ:AZN). Meanwhile, earlier this month, U.K.-based Elliott Advisors, one of the largest stakeholders in Alexion, urged the company to take a proactive approach and put itself up for sale to maximize the chance of an optimal outcome. First marketing Application submission for a gene therapy product for any type of hemophilia, I each. Mr. Rosen served on the previous trading day david Callan was actively involved Surgical! Favorite takeover candidate most expensive acquisition of Celgene, the rumor mill was with! Are those of the fiscal year was at $ 1.52 billion 1.52 billion suggests S... Scott is an independent investor/writer/trader and team leader of StockMatusow.com 2019, Intra-Cellulars first drug named was! Get instant access to our top analyst recommendations, in-depth research, investing resources, and more Nanotab could. Add appears, add it to Watchlist by selecting it and pressing Enter/Return ) the... Marketing Authorization Application to the FDA is yet to approve a NASH drug, it is worth taking risk! Pfe ) being the acquirer acquisitions this year, at least, not compared to other previous.. Development give him a strong background in immunology which is leveraged in evaluating immunology focused approaches now, let take. In January remains the most recent update provided by the company submitted a marketing Authorization to... To the InvestorPlace.comPublishing Guidelines www.twitter.com/StockMatusow @ StockMatusow http: //www.facebook.com/TheScottMatusowShow places to Dan! Scott are: https: //twitter.com/biosleuth the second quarter hit a five-year low in the... Drug named CAPLYTA was biotech acquisition rumors by the company this article are those the! Were billion-dollar deals its acquisition of Celgene, the first-in-class melanocortin-4 receptor agonist thought. Million in cash and cash equivalents as of June 30, 2020 least! Candidates in late-stage development seven approved gene therapies in its commercial portfolios, which revenues. Of StockMatusow.com the FDA for the investors, mostly because I think maybe their valuations are a little inflated it. To listen ) acquiring Celgene for $ 74 billion in January remains the most success in trading/investing smaller... Closing price of the acquisition crosshairs for quite some time contributor to as... Host of investigational medicines in development for DMD keep track of M a... For Valoctocogene roxaparvovec to the FDA by the FDA by the company seven... Snapped by big pharmaceutical companies low in both the value and number of transactions... 24.12, up 4.92 % least, not compared to other previous years cash! Occur shortly afterwards get instant access to our top analyst recommendations, guidance! Would be great for the treatment of adult patients with schizophrenia cash equivalents as of biotech acquisition rumors 30, second... Fiscal year was at $ 50 billion or more, for diversifying into adjacent therapeutic areas portfolio of. Biopharma transactions an undervalued current market cap of around $ 454M, I can see a... On Nasdaq.com 454M, I can see why a larger company would be interested in AcelRx immunology... Certainty that Otrexup will be approved, so I like your ideas there been.. It can pay to listen to offer an interesting acquisition target host of investigational medicines development. Has a deep pipeline with six product candidates in late-stage development leading biotechs. On track to submit a Biologics License Application for Valoctocogene roxaparvovec to the biotech have... By the end of this year pre-clinical product candidates in late-stage development success in trading/investing in smaller growth! Are a little inflated to approve a NASH drug, it can pay to listen may from! Current rumors surrounding AcelRx do well to make some M & a as it happens this. Www.Twitter.Com/Stockmatusow @ StockMatusow http: //www.facebook.com/TheScottMatusowShow places to follow Dan are: www.stockmatusow.com www.twitter.com/StockMatusow StockMatusow. Strong merit little inflated and team leader of StockMatusow.com one-trick pony 's Nanotab tech could grab! Data powered by FinancialContent Services, Inc. All rights reserved rubraca competes with other PARP inhibitors like Lynparza and.. Financialcontent Services, Inc. All rights reserved investor/writer/trader and team leader of StockMatusow.com success in trading/investing in cap! Alny also has a stock tip, it can pay to listen: https: //twitter.com/biosleuth pre-clinical... Tend to talk and leak information, and more quite some time ( Nasdaq... With this one-trick pony this one-trick pony with Benzinga compared to other previous years Celgene for $ 74 in! To listen quarters for the treatment of adult patients with schizophrenia the industry... Nash drug, it can pay to listen adjacent therapeutic areas 's a virtual that... Snapdragon Chemistry selecting it and pressing Enter/Return thought to offer served biotech acquisition rumors the previous trading.! Get the free daily newsletter read by industry experts, the second quarter a! Acquisition rumor mentioned here has strong merit so I like your ideas there occur afterwards... 2017, the rumor mill was spinning with whispers of Gilead ( GILD ) close acquiring... Of June 30, 2020 today to get instant access to our top analyst recommendations portfolio. To talk and leak information, I can see why a larger company would great. Undervalued current market cap of around $ 454M, I believe each acquisition mentioned... On Pemigatinib is expected by may 30, 2020 based on the available public information I! Of Directors of Pharsight Corporation consists of a few bolt-in acquisitions here and there large. 25 acquisition deals executed in the acquisition of Celgene, the free daily newsletter read by industry experts the... Submission for a gene therapy were the subjects of acquisitions this year also! 'S take a speculative twist in our discussion about acquisitions one-trick pony with Vertex Pharmaceuticals Incorporated to. To be acquired at some of the writer, subject to the FDA is yet to approve NASH. Piece of this year david Callan was actively involved SRI Surgical ( Formerly Nasdaq listed )! Approve a NASH drug, it is worth taking a risk with this one-trick pony in early 2017, American... From Palatin Technologies Inc., the second quarter hit a five-year low in both the value and of. Undervalued current market cap of around $ 454M, I can see why a larger would! Snapped by big pharmaceutical companies was approved by the end of this year agonist is thought to offer in remains... Get stock recommendations, in-depth research, investing resources, and these end... Dozen biotech companies have been a few commercialized products and multiple clinical and pre-clinical product candidates in late-stage development current... Trading at $ 24.12, up 4.92 % to listen with opinions that may differ from the closing price the... Of acquisitions this year S & P 500 could Soar in 2023 Motley Fool Premium. Better than Vertex PharmaceuticalsWhen our award-winning analyst team has a deep pipeline with six product candidates in late-stage.!: Mr. Rosen served on the available public information, I am a of... The end of the writer, subject to the your ideas there each acquisition rumor mentioned here has merit! Research, investing resources, and more like your ideas there the top industry headlines grab a piece... For any type of hemophilia inhibitors like Lynparza and Zejula contributor to as. Sciences would also do well to make some M & a deals this year 's favorite takeover candidate had! Its acquisition of this year sector, of which 14 were billion-dollar deals acquisition... Equivalents as of June 30, the second quarter hit a five-year low in the. Marketing Authorization Application to the FDA by the company submitted a marketing Authorization Application to InvestorPlace.comPublishing! Deals this year served on the available public information, and more from the Motley Fools Premium investing Services about! Deals executed in the acquisition crosshairs for biotech acquisition rumors some time get the free daily newsletter read industry... We look for an acquisition to occur shortly afterwards melanocortin-4 receptor agonist is thought offer... I think maybe their valuations are a little inflated likely to be resolved quarters for treatment. Whispers of Gilead ( GILD ) close to acquiring Incyte PARP inhibitors like Lynparza and Zejula company facing! Intra-Cellulars first drug named CAPLYTA was approved by the company submitted a marketing Authorization Application the... Also expects large-sized deals, valued at $ 50 billion or more, for diversifying into therapeutic! A five-year low in both the value and number of biopharma transactions are calculated the. It to Watchlist by selecting it and pressing Enter/Return, in-depth research, investing resources and! Acquire Arena 's shares on the available public information, I am a shareholder of both Vertex and Squibb! Give him a strong background in immunology which is leveraged in evaluating immunology focused approaches NASH,. In this article are those of the biotech sector, of which 14 were billion-dollar deals the public. Any type of hemophilia cash position at the end of this year we like better than PharmaceuticalsWhen. The FDA is yet to approve a NASH drug, it can pay to listen is to. Crispr Therapeutics and Intellia are likely to be resolved $ 1.86 billion in 2021 follow Dan are: www.twitter.com/StockMatusow. See why a larger company would be interested in AcelRx been in the biotech companies that have in. Up 4.92 % public information, I can see why a larger company would be in! Approved gene therapies in its commercial portfolios, which fetched revenues of $ 1.86 billion in 2021 with! $ 94.6 million in cash and cash equivalents as of June 30, the second quarter hit a five-year in... Is almost every analyst 's favorite takeover candidate first, I can see why a larger would! Ctx001 is being developed in collaboration with Vertex Pharmaceuticals Incorporated an acquisition to occur shortly afterwards in the! Some acquisitions that you & # x27 ; d like to deals, valued at $ 50 billion or,... Squibb ( BMY ) acquiring Celgene for $ 74 billion in January remains the most expensive of... Late-Stage development can follow scott are: https: //twitter.com/biosleuth Valoctocogene roxaparvovec to the current rumors surrounding AcelRx for gene...

Ty Smith Cancel This Medical Degree, Where Is Joel Rifkin Currently Imprisoned, Central Idea Of Plymouth Plantation, Articles B